MXPA02008654A - Formulaciones de ranolazina de liberacion prolongada. - Google Patents

Formulaciones de ranolazina de liberacion prolongada.

Info

Publication number
MXPA02008654A
MXPA02008654A MXPA02008654A MXPA02008654A MXPA02008654A MX PA02008654 A MXPA02008654 A MX PA02008654A MX PA02008654 A MXPA02008654 A MX PA02008654A MX PA02008654 A MXPA02008654 A MX PA02008654A MX PA02008654 A MXPA02008654 A MX PA02008654A
Authority
MX
Mexico
Prior art keywords
ranolazine
sustained release
release ranolazine
aqueous media
ranolazine formulations
Prior art date
Application number
MXPA02008654A
Other languages
English (en)
Inventor
Andrew A Wolff
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24074628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02008654(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of MXPA02008654A publication Critical patent/MXPA02008654A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Se describe una formulacion de ranolazina de liberacion prolongada que contiene una mezcla intima de ranolazina y un aglomerante dependiente del pH parcialmente neutralizado para formar una pelicula que es principalmente insoluble en un medio acuoso debajo de un pH 4.5 y soluble en un medio acuoso arriba de un pH 4.5. La formulacion es apropiada para la administracion de ranolazina dos veces al dia y es util para controlar la proporcion de disolucion de ranolazina y para mantener los niveles de ranolazina en el plasma humano en entre 850 y 4000 ng base/ml.
MXPA02008654A 2000-03-08 2001-03-07 Formulaciones de ranolazina de liberacion prolongada. MXPA02008654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/520,932 US6479496B1 (en) 1998-09-10 2000-03-08 Methods for treating angina with ranolazine
PCT/US2001/007287 WO2001066093A2 (en) 2000-03-08 2001-03-07 Sustained release ranolazine formulations

Publications (1)

Publication Number Publication Date
MXPA02008654A true MXPA02008654A (es) 2004-09-06

Family

ID=24074628

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008654A MXPA02008654A (es) 2000-03-08 2001-03-07 Formulaciones de ranolazina de liberacion prolongada.

Country Status (17)

Country Link
US (1) US6479496B1 (es)
EP (1) EP1263439A2 (es)
JP (2) JP4108980B2 (es)
CN (1) CN1323664C (es)
AU (3) AU4009201A (es)
BR (1) BR0109091A (es)
CA (1) CA2402222C (es)
CZ (1) CZ20022996A3 (es)
HK (1) HK1058003A1 (es)
HU (1) HUP0204409A3 (es)
IL (1) IL151575A0 (es)
MX (1) MXPA02008654A (es)
NO (1) NO20024270L (es)
NZ (1) NZ521292A (es)
PL (1) PL357273A1 (es)
RU (1) RU2002126615A (es)
WO (1) WO2001066093A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
JP4546824B2 (ja) 2002-05-21 2010-09-22 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を処置する方法
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US8313775B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1658034A4 (en) 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
JP2007513869A (ja) 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
JP2008526879A (ja) * 2005-01-06 2008-07-24 シーブイ・セラピューティクス・インコーポレイテッド ラノラジンを含有する徐放性薬学的処方物
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CN100455288C (zh) * 2006-06-26 2009-01-28 哈药集团制药总厂 一种盐酸雷诺嗪制剂配方
US20080031947A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. Orally dissolvable/disintegrable lyophilized dosage forms containing protected
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
JP2010520291A (ja) * 2007-03-07 2010-06-10 コンサート ファーマシューティカルズ インコーポレイテッド 抗狭心症化合物としての重水素化ピペラジン誘導体
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20080299195A1 (en) * 2007-05-31 2008-12-04 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
BRPI0721741A2 (pt) * 2007-05-31 2013-02-13 Cv Therapeutics Inc mÉtodo de tratamento de diabetes
JP2010529994A (ja) * 2007-06-13 2010-09-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ピペラジン
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
NO3175985T3 (es) 2011-07-01 2018-04-28
US20140221286A1 (en) 2011-09-21 2014-08-07 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
ATE223218T1 (de) * 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
JP2000336032A (ja) * 1999-05-26 2000-12-05 Kissei Pharmaceut Co Ltd ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物

Also Published As

Publication number Publication date
EP1263439A2 (en) 2002-12-11
CN1443069A (zh) 2003-09-17
WO2001066093A2 (en) 2001-09-13
PL357273A1 (en) 2004-07-26
RU2002126615A (ru) 2004-03-20
HUP0204409A3 (en) 2005-04-28
JP4108980B2 (ja) 2008-06-25
AU4009201A (en) 2001-09-17
CA2402222A1 (en) 2001-09-13
JP2008069159A (ja) 2008-03-27
HUP0204409A2 (en) 2003-05-28
NZ521292A (en) 2008-07-31
US6479496B1 (en) 2002-11-12
NO20024270D0 (no) 2002-09-06
CZ20022996A3 (cs) 2003-09-17
JP2003525896A (ja) 2003-09-02
HK1058003A1 (en) 2004-04-30
NO20024270L (no) 2002-11-06
CA2402222C (en) 2009-11-03
WO2001066093A3 (en) 2002-03-14
CN1323664C (zh) 2007-07-04
AU2001240092B2 (en) 2004-10-14
AU2001240092B8 (en) 2004-12-02
IL151575A0 (en) 2003-04-10
BR0109091A (pt) 2005-02-15
AU2008212005A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
MXPA02008654A (es) Formulaciones de ranolazina de liberacion prolongada.
WO2000013686A3 (en) Sustained release ranolazine formulations
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
AU2001263228A1 (en) Rapidly disintegrating solid oral dosage form
MY118371A (en) Tetrahydrolipstatin containing compositions
YU86003A (sh) Jednodnevne formulacije oksikodona
NO20083842L (no) Anvendelse av opploselig lymfotoksin-beta-reseptor for fremstilling av medikamenter
DE69519300D1 (de) Stabiles arzneimittel enthaltend oxaliplatin
ME00436B (me) Tableta za produženo oslobadjanje gliklazida posle oralne primene
IL143375A0 (en) Sustained release matrix systems for highly soluble drugs
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
GB2373726B (en) Pharmaceutical formulations containing zolmitriptan
AP2003002763A0 (en) Controlled release formulations for oral administration
WO2002011694A3 (en) COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
HK1045937A1 (en) Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
SE0001916D0 (sv) Novel formulation
HRP20030762A2 (en) A stable pharmaceutical formulation comprising torsemide modofication ii
HK1036413A1 (en) Solution comprising prostaglandins and benzyl alcohol.

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights